JP2018538267A - ベンズイミダゾール化合物の過飽和組成物 - Google Patents

ベンズイミダゾール化合物の過飽和組成物 Download PDF

Info

Publication number
JP2018538267A
JP2018538267A JP2018526144A JP2018526144A JP2018538267A JP 2018538267 A JP2018538267 A JP 2018538267A JP 2018526144 A JP2018526144 A JP 2018526144A JP 2018526144 A JP2018526144 A JP 2018526144A JP 2018538267 A JP2018538267 A JP 2018538267A
Authority
JP
Japan
Prior art keywords
bilastin
acid
aqueous solution
organic carboxylic
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018526144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538267A5 (enExample
Inventor
エレーロ、ゴンサロ エルナンデス
エレーロ、ゴンサロ エルナンデス
ロヨ、ビクトル ルビオ
ロヨ、ビクトル ルビオ
ドミンゲス、ネフタリ ガルシア
ドミンゲス、ネフタリ ガルシア
モリ、ゴンサロ カナル
モリ、ゴンサロ カナル
テソン、ニコラス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Faes Farma SA
Original Assignee
Faes Farma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma SA filed Critical Faes Farma SA
Publication of JP2018538267A publication Critical patent/JP2018538267A/ja
Publication of JP2018538267A5 publication Critical patent/JP2018538267A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2018526144A 2015-11-20 2016-11-18 ベンズイミダゾール化合物の過飽和組成物 Withdrawn JP2018538267A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15382574.0 2015-11-20
EP15382574.0A EP3170816A1 (en) 2015-11-20 2015-11-20 Supersaturated compositions of benzimidazole compounds
PCT/EP2016/078154 WO2017085265A1 (en) 2015-11-20 2016-11-18 Supersaturated compositions of benzimidazole compounds

Publications (2)

Publication Number Publication Date
JP2018538267A true JP2018538267A (ja) 2018-12-27
JP2018538267A5 JP2018538267A5 (enExample) 2019-07-11

Family

ID=54707730

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018526144A Withdrawn JP2018538267A (ja) 2015-11-20 2016-11-18 ベンズイミダゾール化合物の過飽和組成物

Country Status (6)

Country Link
US (1) US20180344854A1 (enExample)
EP (2) EP3170816A1 (enExample)
JP (1) JP2018538267A (enExample)
ES (1) ES2778434T3 (enExample)
PT (1) PT3377479T (enExample)
WO (1) WO2017085265A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019076798A1 (en) 2017-10-16 2019-04-25 Faes Farma, S.A. AQUEOUS COMPOSITIONS COMPRISING BILASTIN AND MOMETASONE
CN116211795B (zh) * 2022-12-26 2025-09-26 深圳市贝美药业有限公司 一种比拉斯汀口服液体制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US818454A (en) * 1904-04-06 1906-04-24 Andrew Krus Lathe-dog.
ES2048109B1 (es) 1992-07-20 1994-12-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
ES2124167B1 (es) 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
EP1505066B1 (en) * 2002-04-19 2006-12-06 Faes Farma, S.A. Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic
US20080132419A1 (en) * 2006-10-04 2008-06-05 Nair Rodriguez-Hornedo Dissolution and precipitation of cocrystals with ionizable components
CN103351380B (zh) * 2013-06-30 2019-01-22 北京万全德众医药生物技术有限公司 一种制备比拉斯汀的方法

Also Published As

Publication number Publication date
US20180344854A1 (en) 2018-12-06
EP3377479B1 (en) 2020-01-29
EP3170816A1 (en) 2017-05-24
EP3377479A1 (en) 2018-09-26
WO2017085265A1 (en) 2017-05-26
PT3377479T (pt) 2020-04-02
ES2778434T3 (es) 2020-08-10

Similar Documents

Publication Publication Date Title
CN109769392B (zh) 苯并咪唑衍生物的酸加成盐
JP6609065B2 (ja) １−（５−（２，４−ジフルオロフェニル）−１−（（３−フルオロフェニル）スルホニル）−４−メトキシ−１ｈ−ピロール−３−イル）−ｎ−メチルメタンアミンの新規な酸付加塩
KR101019451B1 (ko) 이마티닙 메실레이트의 다형 및 신규한 결정형과 비결정형및 α형의 제조 방법
TWI624447B (zh) 吡咯衍生物的結晶及其製造方法
TWI647224B (zh) 激酶抑制劑化合物的多晶型、含其的藥物組合物及其製備方法和應用
KR20130042498A (ko) 닐로티닙 염 및 이의 결정형
WO2017008773A1 (en) Crystalline forms of obeticholic acid
JP2023518552A (ja) Ｌｎｐ０２３の結晶形態
CA2878360C (en) Novel solid forms of phosphodiesterase type 5 inhibitors
JP2018538267A (ja) ベンズイミダゾール化合物の過飽和組成物
JP2011037844A (ja) ２−［［［２−［（ヒドロキシアセチル）アミノ］−４−ピリジニル］メチル］チオ］−ｎ−［４−（トリフルオロメトキシ）フェニル］−３−ピリジンカルボキサミドのベンゼンスルホン酸塩、その結晶、その結晶多形およびそれらの製造方法
AU2011284341A1 (en) N-Methylformamide solvate of dasatinib
JP2018535223A (ja) ベンズイミダゾール化合物の共結晶
KR102756414B1 (ko) 고체 형태의 스테모스피로닌 및 이의 염
KR20230114177A (ko) 벤즈이미다졸 유도체의 공동 무정형 고형체
EP4105215A1 (en) Co-crystal of apixaban with a carboxylic acid
HK1253978B (en) Co-crystals of bilastine
TW202426424A (zh) 內匹司他酸加成鹽的多晶型及其製備方法和用途
AU2013203194B2 (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2016127965A1 (en) Solid forms of dolutegravir salts and a method of their preparation
WO2012177708A1 (en) Paliperidone oleate
CA3170562A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine
HK1258115A1 (zh) 用於治疗呼吸道合胞病毒感染的4-喹唑啉胺衍生物的晶形
HK1258115B (en) Crystalline forms of 4-quinazolinamine derivative for the treatment of respiratory syncytial virus infections
HK1169101A (en) 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190604

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200128